Alivus Life Sciences Stock Price Analysis and Quick Research Report. Is Alivus Life Sciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Alivus Life Sciences. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Alivus Life Sciences has a PE ratio of 23.3839391344378 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Alivus Life Sciences has ROA of 13.3384% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Alivus Life Sciences has a Current ratio of 4.9667.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Alivus Life Sciences has a ROE of 18.9377%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Alivus Life Sciences has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

• Sales growth: Alivus Life Sciences has reported revenue growth of 4.5405% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Alivus Life Sciences for the current financial year is 28.597284157923%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Alivus Life Sciences is Rs 5 and the yield is 0.5294%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Alivus Life Sciences is Rs 40.4038. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Alivus Life Sciences in Ticker for free. Also, one can get the intrinsic value of Alivus Life Sciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Alivus Life Sciences FAQs

Q1. What is Alivus Life Sciences share price today?
Ans: The current share price of Alivus Life Sciences is Rs 944.8.

Q2. What is the market capitalisation of Alivus Life Sciences?
Ans: Alivus Life Sciences has a market capitalisation of Rs 11590.93375904 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Alivus Life Sciences?
Ans: The PE ratio of Alivus Life Sciences is 23.3839391344378 and the P/B ratio of Alivus Life Sciences is 3.95734544551341, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Alivus Life Sciences share?
Ans: The 52-week high share price of Alivus Life Sciences is Rs 1335.1, and the 52-week low share price of Alivus Life Sciences is Rs 850.

Q5. Does Alivus Life Sciences pay dividends?
Ans: Currently, Alivus Life Sciences pays dividends. Dividend yield of Alivus Life Sciences is around 0.5294%.

Q6. What are the face value and book value of Alivus Life Sciences shares?
Ans: The face value of Alivus Life Sciences shares is Rs 2, while the book value per share of Alivus Life Sciences is around Rs 238.7459. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Alivus Life Sciences?
Ans: Alivus Life Sciences has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Alivus Life Sciences?
Ans: The ROE of Alivus Life Sciences is 18.9377% and ROCE of Alivus Life Sciences is 25.4984%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Alivus Life Sciences a good buy for the long term?
Ans: The Alivus Life Sciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Alivus Life Sciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Alivus Life Sciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Alivus Life Sciences’s financials?
Ans: You can review Alivus Life Sciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.